Adaptimmune Therapeutics: Q3 Earnings Insights


Adaptimmune Therapeutics ADAP reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM.

Here's what investors need to know about the announcement.


Adaptimmune Therapeutics their estimated earnings by 15.38%, reporting an EPS of $-0.3 versus an estimate of $-0.26, which surprised analysts.

Revenue was up $10,000 from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.0, which was followed by a 3.48% increase in the share price the next day.

Here's a look at Adaptimmune Therapeutics's past performance:


Quarter Q2 2021 Q1 2021 Q4 2020 Q3 2020
EPS Estimate -0.24 -0.25 -0.23 -0.25
EPS Actual -0.24 -0.24 -0.24 -0.24
Revenue Estimate 1.36M 1.83M 1.98M 870.00K
Revenue Actual 3.10M 434.00K 1.50M 1.19M

To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!